Therefore, better benefits may be achieved when immunotherapeutic drugs (PD1/PDL-1/PD-L2/CTLA-4 blockers) are used for colon cancer patients in the low-risk score group. This evidence concerns the gene CD274 and malignant colon neoplasm.